Satralizumab monotherapy effective for seropositive NMOSD
This phase 3 study assessed the safety and efficacy of satralizumab monotherapy for neuromyelitis optica spectrum disorder (NMOSD). Source: AAO
- Posted on: Jul 1 2020
- Leave a response
This phase 3 study assessed the safety and efficacy of satralizumab monotherapy for neuromyelitis optica spectrum disorder (NMOSD). Source: AAO
Tel: 518-580-0553
Get Directions »
Tel: 518-580-0553
Get Directions »
Tel: +1 (518) 580-0553
Get Directions »